Pharmacological Advances in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Progression to Liver Cancer: Molecular Mechanisms, Biomarkers, and Therapeutic Strategies

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), previously known as NAFLD, has emerged as the leading cause of chronic liver disease globally, paralleling the rising epidemics of obesity and type 2 diabetes. While the early stages of the disease are characterized by simple steatosis, a significant proportion of patients progress to Metabolic Dysfunction-Associated Steatohepatitis (MASH), fibrosis, and cirrhosis. Critically, MASLD is rapidly becoming the fastest-growing indication for Hepatocellular Carcinoma (HCC), often developing in the absence of cirrhosis. This metabolic-to-oncogenic transition represents a complex pharmacological challenge, driven by a distinct tumor microenvironment characterized by chronic low-grade inflammation, lipotoxicity, and insulin resistance.This Research Topic aims to elucidate the pharmacological landscape of preventing and treating the progression of MASLD to advanced fibrosis and liver cancer. Despite the global burden, approved pharmacotherapies specifically targeting the molecular drivers of MASLD-driven HCC remain elusive. Current research must focus on dissecting the intricate signaling pathways—such as those involving oxidative stress, mitochondrial dysfunction, and adipokine signaling—that facilitate malignant transformation. Furthermore, there is an urgent need to validate non-invasive biomarkers that can stratify patients based on their risk of developing HCC and to identify novel therapeutic targets that can halt or reverse this pathological continuum.We welcome the submission of Original Research, Review, Mini-Review, and other relevant article types accepted by the journal that explore pharmacological interventions targeting the intersection of metabolic dysfunction and liver carcinogenesis. We are particularly interested in studies that investigate:• Molecular Mechanisms of Transformation: Pharmacological targeting of signaling pathways (e.g., PI3K/Akt/mTOR, Wnt/β-catenin, NF-κB) involved in the transition from simple steatosis to MASH and HCC.• Drug Repurposing and Novel Agents: Evaluation of anti-diabetic agents (e.g., GLP-1 receptor agonists, SGLT2 inhibitors), nuclear receptor agonists (e.g., FXR, PPAR), and novel small molecules in the prevention of MASLD-associated hepatocarcinogenesis.• Biomarkers and Precision Medicine: Identification and pharmacological validation of circulating biomarkers (miRNAs, metabolomics) for early detection of therapeutic response in MASLD-HCC.• Immuno-Oncology in Metabolic Liver Disease: Investigating how the metabolic tumor microenvironment affects the efficacy of immunotherapies (e.g., immune checkpoint inhibitors) and strategies to overcome resistance. Topic editors: Yuan Liang, Nabil Eid Source: https://www.frontiersin.org/research-topics/78024/pharmacological-advances-in-metabolic-dysfunction-associated-steatotic-liver-disease-masld-and-progression-to-liver-cancer-molecular-mechanisms-biomarkers-and-therapeutic-strategies